ReviewDiagnostics (Basel, Switzerland)2026
Advanced Diffusion MRI in Cervical Cancer: A Comprehensive Review.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced diffusion MRI techniques, particularly intravoxel incoherent motion (IVIM) and diffusion tensor imaging (DTI), have emerged as promising functional imaging tools for improving cervical cancer assessment beyond conventional anatomical MRI. This narrative review summarizes current evidence on the clinical utility of these diffusion-based techniques for tumor characterization, local staging, parametrial invasion, lymph node evaluation, treatment response monitoring, and emerging radiomics applications. Across studies, diffusion-related parameters, especially the apparent diffusion coefficient (ADC) and pure molecular diffusion coefficient (D), tend to be lower in malignant cervical tissues and correlate with increased cellularity, higher tumor grade, and more aggressive disease features. IVIM metrics appear especially useful for differentiating cervical cancer from normal tissue, predicting pelvic lymph node involvement, and detecting early treatment response to chemoradiotherapy or neoadjuvant chemotherapy before substantial morphological regression occurs. In contrast, DTI remains less extensively investigated; however, preliminary findings suggest potential value for evaluating parametrial invasion, stromal disruption, tumor grade, and lymph node metastasis, particularly when integrated with IVIM-derived indices. Although diffusion-derived radiomics may further support risk stratification and treatment-response prediction, the evidence base remains limited by small cohorts, single-center designs, methodological heterogeneity, and insufficient external validation. Overall, IVIM and DTI provide valuable non-invasive insight into cervical cancer biology, but standardized acquisition protocols, reproducible thresholds, and multicenter validation are needed before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.